Unfortunately Caremark doesn’t seem to be one of them. Here are some recently published complaints about them at ConsumerAffairs.com. They’re also linked in this story (the full story which mentions Caremark is living in the Wall Street Journal’s walled garden, so I’ll link to the abbreviated one published in the Pittsburgh Post Gazette instead).
In a nutshell, employers are discovering that many third-party administrators are in the pockets of the insurance companies and are compensated generously for recommending a change to Caremark. Evidently Caremark figures that it’s more profitable to pay the middleman, even when there is a conflict of interest, than it is to honor their PBM obligations and cover prescribed medications.
An excerpt from the WSJ article:
… It is another example of how health-care middlemen can reap profits even as … Strategies says the firm received revenue of $629,012 from a PBM, Caremark Rx Inc
Other Caremark news of note:
- Litigation against Caremark for backdating stock options goes forward. (Follow the money on that one)
- A man is fired after his employer accessed his Caremark medication records and discovered a prescription for an anti-anxiety medication.
- Caremark set the California precedent for holding board members civilly liable for criminal acts, which could come back to bite HP’s Board in the butt with regard to their recent pretexting shenanigans.
- Caremark’s 2nd Quarter profits were above expectations, largely because of their insistence on denying coverage for prescribed medications to consumers who are NOT Medicare or low-income subscribers.
Caremark (NYSE: CMX) was one of the most recent companies within this group to report. CMX generated second-quarter profits of 57 cents per share, two cents above expectations. Net revenues rose 15% primarily because of increases in mail and retail sales. Medicare Part D played a role in the growth, though the company noted that it saw “several major generic introductions” this year. (The cheaper cost of generic drugs makes them more affordable to consumers and more profitable for medical insurers and pharmacy benefit managers.) Citing both business momentum and the impact of share buybacks, CMX raised its guidance for full-year earnings per share to a range of $2.37 and $2.39 per share, from $2.29 and $2.35 per share. The majority of the 18 covering analysts raised their projections in response, causing the full-year estimate to rise by four cents to $2.38 per share.
As for me, I am about to fork over another $400 for Sticks’ meds for the last quarter of the year. I have exhausted my Tier II appeals and am about to go back for another round, but he still has to have the meds.
I think that means this blogger will keep barking.
Technorati Tags: caremark, PBM, sleazy insurance practices






Pingback: Caremark, PBMs, Studies and a Broken System at odd time signatures
Pingback: Caremark Employees Speak » odd time signatures